Valuation: Rezolute Inc

Market Cap 536M 469M 432M 399M 758M 51.11B 770M 5.17B 2.03B 25.18B 2.01B 1.97B 86.56B P/E 2026 *
-7.33x
P/E 2027 * -7.89x
Enterprise Value 536M 469M 432M 399M 758M 51.11B 770M 5.17B 2.03B 25.18B 2.01B 1.97B 86.56B EV / Sales 2026 *
-
EV / Sales 2027 * 233x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute Inc

Manager TitleAgeSince
Chief Executive Officer 58 2013-01-29
Director of Finance/CFO 52 2024-01-22
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 2022-05-03
Director/Board Member 55 2019-11-19
Chairman 68 2019-02-09
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-14.41% - - 536M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-3.67%+2.58%+18.37%+460.88% 25.63B
-1.78%-2.58%-19.67%-14.82% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-1.16%+1.61%+24.92%+195.88% 14.35B
Average -0.82%+1.16%+54.35%+147.07% 26.91B
Weighted average by Cap. -1.23%+0.29%+54.87%+137.39%

Financials

2026 *2027 *
Net sales - 2.3M 2.02M 1.86M 1.72M 3.26M 220M 3.31M 22.21M 8.72M 108M 8.65M 8.46M 372M
Net income -72.7M -63.59M -58.65M -54.17M -103M -6.93B -105M -701M -275M -3.42B -273M -267M -11.74B -75.12M -65.71M -60.61M -55.98M -106M -7.16B -108M -724M -284M -3.53B -282M -276M -12.13B
Net Debt - -
Logo Rezolute Inc
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-